Evidence map›Paper›PMID 40856954›Full record

ArticleGenes & genomics2025

PRDM14 promoted NSCLC cell proliferation, migration and invasion via modulating H3K27me3-mediated PEBP1/Raf-1/MEK/ERK MAPK signaling.

He Shi, Yunfei Jiang, Haijun Mu, Guohua Liu, Xinyue Cheng, Weili Kong, Xingqi Zhou, Xiaoqiang Wen, Xiao Wang, Yiyu Lin and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

He ShiMedical Laboratory Center of Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China.ORCID http://orcid.org/0009-0000-8042-7052
Yunfei JiangDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Haijun MuDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Guohua LiuDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Xinyue ChengDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Weili KongDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Xingqi ZhouDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Xiaoqiang WenDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Xiao WangDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Yiyu LinDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Linyu PanDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Haiying DongDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Hongxia BiDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Lina HeDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China.
Hongyan ZhengDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China. 328077454@qq.com.
Hanbing ShiDepartment of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, 3 Taishun Street, Tiefeng District, Qiqihar, 161000, Heilongjiang, China. shi-hanbing@163.com.

Funding

（A Project Grant From Research Fund of Education Department of Heilongjiang ProvinA Novel Therapeutic Target for Invasion and Metastasis of Lung Adenocarcinoma and Interventions with Chinese Medicine 2019-KYYWY-1216Qiqihar Academy of Medical Sciences Project Research on MET-PI3K-AKt Signaling Pathway Involved in Regulating the TRAIL Sensitivity of Lung Adenocarcinoma Cells QMSI2019L-20
6 · The paper itself

Abstract

backgroundOur previous research revealed that PRDI-BF1 and RIZ homology domain containing protein 14 (PRDM14) accelerated human non-small cell lung cancer (NSCLC) cell migration. However, the internal mechanism remains unclear.

objectiveHerein, we aimed to explore whether PRDM14 modulates NSCLS cell growth and metastasis via H3K27me3-mediated phosphatidylethanolamine-binding protein 1 (PEBP1)/Raf-1/MEK/ERK signaling.

methodsPRDM14 overexpression plasmid (OE-PRDM14), siRNA targeting PRDM14 (si-PRDM14) or si-jumonji domain-containing protein 3 (si-JMJD3) were transfected to alter PRDM14 or JMJD3 expressions. Vemurafenib (VMF) was utilized to inhibit Raf-1/MEK/ERK signaling. Cell proliferation was tested via Edu staining and colony formation assay. Cell migration and invasion were evaluated through two-chamber transwell assay. The protein levels of polycomb repressive complex 2 (PRC2), tri-methylation at lysine 27 of histone H3 (H3K27me3) and PEBP1/Raf-1/MEK/ERK signaling were measured via western blotting. qPCR was used to test mRNA expressions of PEBP1, c-Fos, c-Jun and c-Myc.

resultsOE-PRDM14 promoted A549 cell proliferation, migration and invasion, elevated PRC2 and H3K27me3 expressions, lowered PEBP1 expression and activated Raf-1/MEK/ERK signaling. si-PRDM14 had contrary influences. VMF weakened the influences of OE-PRDM14 on A549 cell functions and Raf-1/MEK/ERK signaling, but had no significant effects on PEBP1 and H3K27me3 levels. si-JMJD3 accelerated the influences of PRDM14 overexpression on A549 cell functions, PEBP1 and H3K27me3 expressions, as well as Raf-1/MEK/ERK signaling.

conclusionsPRDM14 promoted NSCLC proliferation, migration and invasion via modulating PRC2/H3K27me3-mediated PEBP1/Raf-1/MEK/ERK signaling activation. PRDM14 might be as a new target in NSCLC therapy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsTranscription FactorsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHistonesHumansJumonji Domain-Containing Histone DemethylasesMAP Kinase Signaling SystemNeoplasm InvasivenessPhosphatidylethanolamine Binding ProteinProto-Oncogene Proteins c-rafHistonesJumonji Domain-Containing Histone DemethylasesPEBP1 protein, humanPhosphatidylethanolamine Binding ProteinProto-Oncogene Proteins c-rafRaf1 protein, humanTranscription FactorsH3K27me3Jumonji domain-containing protein 3Non-small cell lung cancerPEBP1/Raf-1/MEK/ERK MAPK signalingPolycomb repressive complex 2PRDI-BF1 and RIZ homology domain containing protein 14

Identifiers

PMID40856954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.